# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HOOKIPA Pharma Inc. (NASDAQ:HOOK, ", HOOKIPA", )))), a company developing a new class of immunotherapeutics based on it...
HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and raises the price target from...
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated wi...
RBC Capital analyst Brian Abrahams reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and maintains $5 price target.